https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2010-01-01 / Neurosurg. Clin. N. Am. 2010 Jan;21(1):111-23
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2010-01-01 / Neurosurg. Clin. N. Am. 2010 Jan;21(1):111-232010-01-01 00:00:002019-02-15 08:48:31Heat shock proteins in glioblastomas
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2010-01-01 / Curr. Med. Chem. 2010;17(27):3045-57
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2010-01-01 / Curr. Med. Chem. 2010;17(27):3045-572010-01-01 00:00:002019-02-15 09:17:27Biological rationales and clinical applications of temperature controlled hyperthermia–implications for multimodal cancer treatments
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2009-12-24 / J. Neurooncol. 2010 Jul;98(3):395-405
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2009-12-24 / J. Neurooncol. 2010 Jul;98(3):395-4052009-12-24 00:00:002009-12-24 00:00:00Transcranial electro-hyperthermia combined with alkylating chemotherapy in patients with relapsed high-grade gliomas: phase I clinical results
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2009-12-01 / Int J Hyperthermia 2009 Dec;25(8):610-6
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2009-12-01 / Int J Hyperthermia 2009 Dec;25(8):610-62009-12-01 00:00:002019-02-15 09:17:30Heat shock proteins and immunity: application of hyperthermia for immunomodulation
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2009-11-01 / Radiother Oncol 2009 Nov;93(2):358-63
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2009-11-01 / Radiother Oncol 2009 Nov;93(2):358-632009-11-01 00:00:002019-02-15 09:17:31Quadrimodal treatment of high-risk T1 and T2 bladder cancer: transurethral tumor resection followed by concurrent radiochemotherapy and regional deep hyperthermia
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2009-11-01 / Expert Rev Anticancer Ther 2009 Nov;9(11):1577-82
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2009-11-01 / Expert Rev Anticancer Ther 2009 Nov;9(11):1577-822009-11-01 00:00:002019-02-15 08:48:32Heat-shock protein vaccines as active immunotherapy against human gliomas
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2009-09-22 / Mol. Ther. 2009 Dec;17(12):2049-57
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2009-09-22 / Mol. Ther. 2009 Dec;17(12):2049-572009-09-22 00:00:002019-02-15 08:48:18Abrogation of local cancer recurrence after radiofrequency ablation by dendritic cell-based hyperthermic tumor vaccine
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2009-09-15 / Exp. Dermatol. 2010 Feb;19(2):108-16
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2009-09-15 / Exp. Dermatol. 2010 Feb;19(2):108-162009-09-15 00:00:002019-02-15 08:48:17Enhanced T-cell activation by immature dendritic cells loaded with HSP70-expressing heat-killed melanoma cells
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2009-09-01 / Prostate 2009 Sep;69(12):1343-52
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2009-09-01 / Prostate 2009 Sep;69(12):1343-522009-09-01 00:00:002019-02-15 08:48:19Immunogenicity of 56 degrees C and UVC-treated prostate cancer is associated with release of HSP70 and HMGB1 from necrotic cells
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2009-06-01 / Curr Opin Investig Drugs 2009 Jun;10(6):550-8
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2009-06-01 / Curr Opin Investig Drugs 2009 Jun;10(6):550-82009-06-01 00:00:002019-02-15 09:17:33Hyperthermia as an immunotherapy strategy for cancer
